Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Smallpox Vaccines
Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
November 19th, 2008
Bavarian Nordic has completed a clinical safety report from a large Phase II study with IMVAMUNE(R) in HIV infected subjects that confirms the excellent safety profile of IMVAMUNE(R). Within the next few days the safety report of this study will be submitted to the FDA and this will trigger a USD 25 million milestone payment under the RFP-3 contract. The clinical safety report constitutes a major part of the data package that will be used to potentially support the use of IMVAMUNE(R) in a declared emergency. In support of using IMVAMUNE(R) as a smallpox vaccine in individuals otherwise contraindicated to receive conventional vaccinia vaccines, Bavarian Nordic has...
Source: Vaccine Weekly (2008-11-19)
|
